Detalhe da pesquisa
1.
Circulating Tumor DNA as a Predictive Biomarker for Clinical Outcomes With Margetuximab and Pembrolizumab in Pretreated HER2-Positive Gastric/ Gastroesophageal Adenocarcinoma.
Oncology (Williston Park)
; 37(4): 176-183, 2023 04 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-37104758
2.
Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22-05): a single-arm, phase 1b-2 trial.
Lancet Oncol
; 21(8): 1066-1076, 2020 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-32653053
3.
Margetuximab Versus Trastuzumab in Patients With Previously Treated HER2-Positive Advanced Breast Cancer (SOPHIA): Final Overall Survival Results From a Randomized Phase 3 Trial.
J Clin Oncol
; 41(2): 198-205, 2023 01 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-36332179